Small Pharma Is On A Patenting Streak
Last week, Patent Forecast highlighted London-based Small Pharma’s Phase I Trial Results for its DMT-assisted therapy for Major Depressive Disorder (MDD) treatment. With Phase II Trials on the horizon, two more patent applications (U.S.…
Promising DMT Phase I Trial Results Released by Small Pharma
Psychedelic therapies are growing in interest across the world. In Texas, the government has begun studying the efficacy of psilocybin in treating PTSD in veterans. Now, neuroscience company, Small Pharma, Inc., has more insight into the…
This Inhaler Company Could be Big Tobacco’s Next Target for Acquisition
Philip Morris International took the world by surprise when it announced it would acquire Vectura Group, an inhaler technology and platform company, in September 2021. The main concern - what is Philip Morris going to do with a company…
What’s Philip Morris’ Intention with Vectura?
Speculations arose with the September 2021 Philip Morris International (PMI) acquisition of inhaler maker Vectura Group. Philip Morris said the acquisition is part of its long-term plan to become “smoke-free” and a “broader healthcare and…
The US Government is Interested in Psychedelics
In cooperation with Yale University, The Department of Veterans Affairs could be looking into treating mood disorders using psychedelics. Arising from NIH grant MH101498 is a patent application with claims for treating or preventing a mood…
Should the Psychedelics Industry Worry about the Compass Pathways Psilocybin Patent?
Psychedelics are becoming the new cannabis. University and private company interest has grown quickly over the last 5 years. Many companies like MindMed and NeonMind have announced their filings of provisional patent applications and are…
You Aren’t Tripping – Oregon Legalized Psilocybin
Oregon voted in favor of legalizing medicinal psilocybin in 2020, otherwise known as magic mushrooms. Cities all around the US have begun decriminalizing psychedelics with Washington, D.C. being the latest to hop on board. Oregon is now…
CB Therapeutics Elevates Cannabinoid Biosynthesis Race
Having made its first commercial sale of rare cannabinoids back in June of 2020, CB Therapeutics is continuing to stake its claims in cannabinoid biosynthesis, receiving its second patent on April 20, 2021. This patent discloses a process…
Two illegal patents in one week? Grab your popcorn
The state of Washington has yet to legalize psychedelics like psilocybin; however, Washington-based psychedelics medication developer CaaMTech, LLC is betting on near-future legalization of the drug. CaaMTech received itsfirst patent for a…
Patent Forecast® gives you AI-driven, interactive data that identifies key innovators and first movers.
